Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 96.18 with a ...

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

Recently, Regeneron Pharmaceuticals saw a wave of analyst upgrades from major banks such as Bank of America Securities and ...

Fintel reports that on January 7, 2026, B of A Securities upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...

Regeneron Pharmaceuticals will release its fourth-quarter earnings later this month, and analysts anticipate a double-digit ...

Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:REGN), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S.

A court hearing to consider the transaction’s approval is scheduled for June 17, according to 23andMe Justin Sullivan/Getty; Michael Nagle/Bloomberg via Getty Genetics company 23andMe is expected to ...